The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.

Trial Profile

The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Fibrinogen (Primary)
  • Indications Postoperative haemorrhage
  • Focus Therapeutic Use
  • Acronyms RiaSTAP
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
    • 05 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top